ENTHERA PHARMACEUTICALS RAISES €28 MILLION IN SERIES A FINANCING TO ADVANCE RESTORATIVE THERAPY FOR TYPE 1 DIABETES AND INFLAMMATORY BOWEL DISEASE
Enthera Pharmaceuticals announced the completion of a €28 million financing round, the largest international VC-backed Series A financing round for biotech in Italy to date! We are particularly proud to announce it, since Enthera is BiovelocITA’s fist spin-off and BiovelocITA provided the initial seed fund for the start-up. This financing perfectly reflects our mission to transform breakthrough science into full-fledged enterprises. Enthera is a salient example of what can be achieved when the critical components of a biotech ecosystem are brought together to accelerate innovation in Italy: World-class scientific founders as Paolo Fiorina and Francesca D'Addio, experienced managers as Enthera CEO Giovanni Amabile and BiovelocITA managers Maria Gabriella Camboni and Silvano Spinelli, and dedicated financial capital as the one obtained from Sofinnova Partners. Congratulations, Giovanni Amabile, and the entire Enthera team for the achievement!